Here we have shown that β-cytoplasmic actin acts as a tumor suppressor, inhibiting cell growth and invasion in vitro and tumor growth in vivo. In contrast, γ-cytoplasmic actin increases the oncogenic potential via ERK1/2, p34-Arc, WAVE2, cofilin1, PP1 and other regulatory proteins. There is a positive feedback loop between γ-actin expression and ERK1/2 activation. We conclude that non-muscle actin isoforms should not be considered as merely housekeeping proteins and the β/γ-actins ratio can be used as an oncogenic marker at least for lung and colon carcinomas. Agents that increase β- and/or decrease γ-actin expression may be useful for anticancer therapy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4546487 | PMC |
| http://dx.doi.org/10.18632/oncotarget.3989 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Divergent Contribution of Cytoplasmic Actins to Nuclear Structure of Lung Cancer Cells.
Int J Mol Sci
December 2024
Scientific Research Institute of Carcinogenesis, N.N. Blokhin National Medical Research Center of Oncology, 115478 Moscow, Russia.
A growing body of evidence suggests that actin plays a role in nuclear architecture, genome organisation, and regulation. Our study of human lung adenocarcinoma cells demonstrates that the equilibrium between actin isoforms affects the composition of the nuclear lamina, which in turn influences nuclear stiffness and cellular behaviour. The downregulation of β-actin resulted in an increase in nuclear area, accompanied by a decrease in A-type lamins and an enhancement in lamin B2.
View Article and Find Full Text PDFAmoeboid cells undergo durotaxis with soft end polarized NMIIA.
Elife
December 2024
Institute of Systems Biomedicine, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, China.
Cell migration towards stiff substrates has been coined as durotaxis and implicated in development, wound healing, and cancer, where complex interplays between immune and non-immune cells are present. Compared to the emerging mechanisms underlying the strongly adhesive mesenchymal durotaxis, little is known about whether immune cells - migrating in amoeboid mode - could follow mechanical cues. Here, we develop an imaging-based confined migration device with a stiffness gradient.
View Article and Find Full Text PDFSuppression of non-muscle myosin II boosts T cell cytotoxicity against tumors.
Sci Adv
November 2024
State Key Laboratory of Common Mechanism Research for Major Diseases, Department of Pharmacology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Increasing evidence highlights the importance of immune mechanoregulation in establishing and sustaining tumor-specific cytotoxicity required for desirable immunotherapeutic outcomes. However, the molecular connections between mechanobiological inputs and outputs and the designated immune activities remain largely unclear. Here, we show that partial inhibition of non-muscle myosin II (NM II) augmented the traction force exerted by T cells and potentiated T cell cytotoxicity against tumors.
View Article and Find Full Text PDFTensions on the actin cytoskeleton and apical cell junctions in the spermatheca are influenced by spermathecal anatomy, ovulation state and activation of myosin.
Front Cell Dev Biol
October 2024
Department of Biology, Northeastern University, Boston, MA, United States.
Article Synopsis
- Cells generate mechanical forces primarily through myosin acting on the actin cytoskeleton, particularly in the spermatheca where they drive muscle-like contractions during oocyte fertilization.
- Researchers used advanced techniques like laser ablation and RNA interference to investigate how myosin activity affects force distribution and tissue response in spermathecal cells.
- Findings indicated that while tension exists in the basal actomyosin fibers due to embryo presence, altering myosin activity affects both basal and apical tensions, suggesting a complex interaction between these forces.
Article Synopsis
- Non-muscle myosin II (NMII) plays a crucial role in biological processes, but current therapeutic options are limited due to non-selective inhibitors like blebbistatin that affect both NMII and cardiac myosin II (CMII).
- Researchers developed a series of selective NMII inhibitors, notably MT-228, which demonstrates high brain penetration and effectiveness in preclinical models for stimulant use disorder, a condition lacking FDA-approved treatments.
- The structure of MT-228 binding to myosin II reveals its 17-fold selectivity for NMII over CMII, providing insights for future drug development and potential applications in various medical fields, including cancer and nerve regeneration.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!